Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

by Henrik Zetterberg, Kaj Blennow
Published 2021-02-01

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress

by Marwan N. Sabbagh, Kaj Blennow
Published 2019-12-01

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

by Carina Wattmo, Kaj Blennow, Oskar Hansson
Published 2020-01-01

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders

by Ulf Andreasson, Kaj Blennow, Henrik Zetterberg
Published 2016-01-01

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease

by Niels Andreasen, Kaj Blennow, Henrik Zetterberg
Published 2010-01-01

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease

by Niklas Mattsson, Henrik Zetterberg, kaj Blennow
Published 2010-01-01

Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease?

by Lucilla Parnetti, Jens Wiltfang, Kaj Blennow
Published 2010-01-01

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems

by Henrik Zetterberg, Niklas Mattsson, Kaj Blennow
Published 2010-01-01

Spitting image: can saliva biomarkers reflect Alzheimer's disease?

by Nicholas J. Ashton, Kaj Blennow, Henrik Zetterberg
Published 2021-06-01

Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage

by Lovisa Tobieson, Henrik Zetterberg, Kaj Blennow, Niklas Marklund
Published 2021-08-01

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

by Niklas Mattsson-Carlgren, Sebastian Palmqvist, Kaj Blennow, Oskar Hansson
Published 2020-12-01

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

by Nicholas J. Ashton, Mark Ide, Henrik Zetterberg, Kaj Blennow
Published 2019-12-01

Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies

by Niklas Mattsson-Carlgren, Sebastian Palmqvist, Kaj Blennow, Oskar Hansson
Published 2021-01-01

No change in plasma tau and serum neurofilament light concentrations in adolescent athletes following sport-related concussion.

by Colin Wallace, Henrik Zetterberg, Kaj Blennow, Paul van Donkelaar
Published 2018-01-01

Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?

by Valter Niemelä, Anne-Marie Landtblom, Kaj Blennow, Jimmy Sundblom
Published 2017-01-01

Commentary: Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

by Thomas K. Karikari, Augustina Charway-Felli, Kina Höglund, Kina Höglund, Kaj Blennow, Kaj Blennow, Henrik Zetterberg, Henrik Zetterberg, Henrik Zetterberg, Henrik Zetterberg
Published 2018-03-01

Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study

by Marie Eckerström, Staffan Nilsson, Henrik Zetterberg, Kaj Blennow, Anna Grahn
Published 2020-12-01

Repeated lumbar punctures within 3 days may affect CSF biomarker levels

by Martin Olsson, Johan Ärlig, Jan Hedner, Kaj Blennow, Henrik Zetterberg
Published 2019-12-01

Increased CSF levels of phosphorylated neurofilament heavy protein following bout in amateur boxers.

by Sanna Neselius, Henrik Zetterberg, Kaj Blennow, Jan Marcusson, Helena Brisby
Published 2013-01-01

Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels

by Victor Bloniecki, Dag Aarsland, Jeffrey Cummings, Kaj Blennow, Yvonne Freund-Levi
Published 2014-08-01